Absci (ABSI) Cash from Investing Activities (2020 - 2026)
Absci (ABSI) posted Cash from Investing Activities of $7.4 million for Q1 2026, down 62.34% sequentially from $19.5 million in Q4 2025, and up 148.94% YoY from $3.0 million in Q1 2025.
Analysis
Absci (ABSI) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Absci has reported Cash from Investing Activities for 7 years, with the latest figure at $7.4 million in Q1 2026.
- Quarterly Cash from Investing Activities rose 148.94% year-over-year to $7.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$27.8 million (down 238.35% YoY) and the FY2025 annual result came in at -$50.2 million, down 20.64% from the prior year.
- Cash from Investing Activities retreated to $7.4 million in Q1 2026 per ABSI's latest filing, from $19.5 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $70.2 million in Q2 2023 and troughed at -$78.7 million in Q3 2022.
- A 5-year average of -$7.6 million and a median of $1.3 million in 2024 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities slumped 1054.3% in 2022, then jumped 725.07% in 2023.
- Over 5 years, Cash from Investing Activities stood at -$30.2 million in 2022, then surged by 162.82% to $19.0 million in 2023, then grew by 0.45% to $19.0 million in 2024, then increased by 2.65% to $19.5 million in 2025, then tumbled by 62.34% to $7.4 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $7.4 million, $19.5 million, and -$63.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Absci | 1.39 Bn | 1.19 Bn | - | 24.07 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 24.07 Mn |
| Mar 31, 2026 | 7.36 Mn |
| Dec 31, 2025 | 19.55 Mn |
| Sep 30, 2025 | -63.70 Mn |
| Jun 30, 2025 | 9.04 Mn |
| Mar 31, 2025 | -15.04 Mn |
| Dec 31, 2024 | 19.04 Mn |
| Sep 30, 2024 | 14.81 Mn |
| Jun 30, 2024 | 1.26 Mn |
| Mar 31, 2024 | -76.68 Mn |
| Dec 31, 2023 | 18.96 Mn |
| Sep 30, 2023 | 20.14 Mn |
| Jun 30, 2023 | 70.15 Mn |
| Mar 31, 2023 | -27.30 Mn |
| Dec 31, 2022 | -30.18 Mn |
| Sep 30, 2022 | -78.72 Mn |
| Jun 30, 2022 | -11.22 Mn |
| Mar 31, 2022 | -6.86 Mn |
| Dec 31, 2021 | -8.32 Mn |
| Sep 30, 2021 | -6.82 Mn |